BioSpace News Archive

On Wednesday, U.S. District Judge Edward Davila set a new date of Oct. 27 to hear the criminal fraud case against Holmes and Theranos’ former president and her former boyfriend, Ramesh “Sunny” Balwani.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

The company suggests its approach can actually help eliminate the virus from an already-infected host, while also bolstering the immune response.

Kubota Vision Inc., formerly known as Acucela Inc., a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the signing of an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 inhibitor compounds discovered by Kubota Vision.

Portage Biotech Inc. wishes to announce that effective April 15, 2020, the Ontario Securities Commission revoked its Failure-to-File Cease Trade Order issued against the Company on August 2, 2019 and that trading of the Company’s common shares on CSE is expected to resume shortly..

Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive health through the industry’s first sperm biology platform, today announced the appointment of Ramiro Castro-Santamaria, M.D., M.P.H., M.B.A., as its Chief Medical Officer. Dr. Castro-Santamaria is a urologist and family medicine physician and brings nearly 20 years of experience in clinical research and drug development across therapeuti

Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced the appointment of Edgardo Baracchini, Ph.D., as chief business officer. Dr. Baracchini will lead the company’s corporate growth strategy, business development and partnership opportunities. “Ed is an accomplished biotechnology executive who has demonstrated his capabi

Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced the appointment of Scott Jackson to its Board of Directors.

Steering Committee to Provide Scientific Oversight and Guidance for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid Leukemia in Second Remission

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2020 financial results on Thursday, May 7 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7 th , at 9:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company’s website a